Renaissance Technologies
EIDX

Renaissance Technologies’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Renaissance Technologies’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,701
Closed -$642K – 3855
2020
Q3 		$642K Sell
12,701
-46,300
-78% -$2.08M ﹤0.01% 2730
2020
Q2 		$2.81M Sell
59,001
-10,000
-14% -$465K ﹤0.01% 1979
2020
Q1 		$3.38M Buy
69,001
+62,918
+1,034% +$3.21M ﹤0.01% 1782
2019
Q4 		$349K Buy
+6,083
New +$301K ﹤0.01% 3030
2019
Q3 		– Sell
-10,700
Closed -$333K – 3837
2019
Q2 		$333K Buy
+10,700
New +$290K ﹤0.01% 3140

Other funds holding EIDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Renaissance Technologies's EIDX Position: Q4 2020 in Review

Renaissance Technologies sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 12,701 shares — an estimated $642K sold.

Renaissance Technologies first reported a position in EIDX in Q2 2019 and held it in 5 quarters. The position peaked at $3.38M in Q1 2020. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

  • Renaissance Technologies reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Renaissance Technologies sold 12,701 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $642K.
  • Renaissance Technologies first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
  • Renaissance Technologies's Eidos Therapeutics, Inc. Common Stock position peaked at $3.38M in Q1 2020.
  • 121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Renaissance Technologies's 13F filing for Q4 2020, filed 10 Feb 2021.